1. Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS‐CoV‐2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo‐controlled trial. Issue 3 (13th July 2022) Authors: Tabarsi, Payam; Anjidani, Nassim; Shahpari, Ramin; Roshanzamir, Khashayar; Fallah, Newsha; Andre, Greiciely; Petrovsky, Nikolai; Barati, Saghar Journal: Immunology Issue: Volume 167:Issue 3(2022) Page Start: 340 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗